<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26552" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pamidronate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ballard</surname>
            <given-names>Travis</given-names>
          </name>
          <aff>LECOM Bradenton</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chargui</surname>
            <given-names>Soumaya</given-names>
          </name>
          <aff>Charles Nicolle's Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Travis Ballard declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Soumaya Chargui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26552.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Pamidronate is a medication used in the management and treatment of moderate or severe hypercalcemia of malignancy, moderate to severe Paget disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma. It is in the bisphosphonate class of medications. This activity describes the indications, action, and contraindications for pamidronate as a valuable agent in treating hypercalcemia of malignancy, Paget disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma). This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the treatment of patients with conditions for which this drug is indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of pamidronate.</p></list-item><list-item><p>Describe the potential adverse effects of pamidronate.</p></list-item><list-item><p>Explain the appropriate monitoring required to evaluate the toxicity of pamidronate.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance pamidronate and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26552&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26552">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26552.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Pamidronate belongs to the drug class known as bisphosphonates, whose therapeutic value stems from their ability to inhibit osteoclast-mediated bone resorption.<xref ref-type="bibr" rid="article-26552.r1">[1]</xref></p>
        <p>FDA-approved indications for pamidronate include moderate or severe hypercalcemia of malignancy, moderate to severe Paget disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.<xref ref-type="bibr" rid="article-26552.r2">[2]</xref><xref ref-type="bibr" rid="article-26552.r3">[3]</xref><xref ref-type="bibr" rid="article-26552.r4">[4]</xref><xref ref-type="bibr" rid="article-26552.r5">[5]</xref><xref ref-type="bibr" rid="article-26552.r6">[6]</xref></p>
        <p>Non-FDA-approved indications for pamidronate include: osteoporosis, complex regional pain syndrome, osteoporosis secondary to chronic glucocorticoid use and prolonged immobility, bone loss, nonmetastatic hormone-responsive prostate cancer, and osteogenesis imperfecta in children.<xref ref-type="bibr" rid="article-26552.r7">[7]</xref><xref ref-type="bibr" rid="article-26552.r8">[8]</xref><xref ref-type="bibr" rid="article-26552.r9">[9]</xref></p>
      </sec>
      <sec id="article-26552.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The mechanism of action of pamidronate, as well as other bisphosphonates, stems from its chemical structure as a derivative of inorganic pyrophosphate (PPi). Bisphosphonates mimic PPi and bind with high affinity to hydroxyapatite crystals found within areas of remodeling bone. The bound drug is released from its bound hydroxyapatite as osteoclasts begin to resorb bone. The freed drug then leads to apoptosis of osteoclasts via inhibition of the enzyme farnesyl pyrophosphate synthase. This enzyme is involved in metabolic pathways responsible for the production of cholesterol and other lipids. Despite the ubiquitous nature of this enzyme, bisphosphonate-induced apoptosis via inhibition of farnesyl pyrophosphate only appears in osteoclasts. Pamidronate and the other newer (nitrogen-containing) bisphosphonates induce osteoclast apoptosis via this mechanism, while earlier (non-nitrogen-containing) bisphosphonates do so via disruption of several intracellular ATP-dependent processes.<xref ref-type="bibr" rid="article-26552.r9">[9]</xref><xref ref-type="bibr" rid="article-26552.r1">[1]</xref></p>
      </sec>
      <sec id="article-26552.s4" sec-type="Administration">
        <title>Administration</title>
        <p>For the treatment of osteolytic lesions of multiple myeloma and bone metastases of breast cancer, IV pamidronate is administered as 90 mg infusions for at least 2 hours and repeated every 3&#x000a0;to 4 weeks.<xref ref-type="bibr" rid="article-26552.r10">[10]</xref><xref ref-type="bibr" rid="article-26552.r5">[5]</xref></p>
        <p>For the treatment of hypercalcemia of malignancy, IV pamidronate administration is a single dose of 90 mg&#x000a0;for 2&#x000a0;to 24 hours.<xref ref-type="bibr" rid="article-26552.r11">[11]</xref></p>
        <p>For the treatment of Paget disease of bone, IV pamidronate is administered as 30 mg over 4 hours on three consecutive days, or 60&#x000a0;to 90 mg infusion over 2&#x000a0;to 4 hours for two or more nonconsecutive days. For mild disease, a single 90 mg infusion may suffice. For severe disease, several 90 mg infusions may be necessary.<xref ref-type="bibr" rid="article-26552.r12">[12]</xref></p>
      </sec>
      <sec id="article-26552.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Pamidronate correlates with numerous adverse effects, including hypocalcemia and resulting secondary hyperparathyroidism, acute phase response, musculoskeletal pain, various ocular events, and osteonecrosis of the jaw.<xref ref-type="bibr" rid="article-26552.r13">[13]</xref></p>
        <p>IV Bisphosphonates, like pamidronate, are more likely to cause symptomatic hypocalcemia than oral medications, which usually occur days after infusion. Prevention of this complication is achievable by making sure&#x000a0;patients receive adequate Vitamin D and calcium supplementation approximately two weeks before bisphosphonate infusion.<xref ref-type="bibr" rid="article-26552.r13">[13]</xref></p>
        <p>An adverse effect similar to the acute phase response can occur following the initial pamidronate infusion, which reaches maximal intensity in 28&#x000a0;to 36 hours and self-resolves in 2&#x000a0;to 3 days. It is rarer following subsequent infusions. Patients with this response complain of fever and symptoms of influenza, such as malaise, fatigue, and generalized body pain.<xref ref-type="bibr" rid="article-26552.r13">[13]</xref>&#x000a0;In addition to the pain described in cases of an acute phase response, pamidronate can lead to a delayed, painful syndrome characterized as severe and debilitating occurring up to years after administering the drug. It can present any time after administration of the drug.<xref ref-type="bibr" rid="article-26552.r13">[13]</xref></p>
        <p>The most common ocular complication following pamidronate use is nonspecific and self-resolving conjunctivitis. More serious ocular complications include scleritis and uveitis, which both warrant immediate discontinuation of the drug.<xref ref-type="bibr" rid="article-26552.r13">[13]</xref></p>
        <p>Osteonecrosis of the jaw (ONJ) is an uncommon but feared side effect of bisphosphonate use. Patients with ONJ may complain of jaw pain, swelling and redness of nearby tissue, loose teeth in the affected region, and the presence of pus.<xref ref-type="bibr" rid="article-26552.r14">[14]</xref>&#x000a0;ONJ affects the mandible more often than the maxilla. It is far more common in those receiving IV bisphosphonates. When due to oral drugs, ONJ is milder and responds better to treatment. The incidence of ONJ increases with increasing dose and duration of administration, and the current recommendation is for the careful use of IV bisphosphonate after two years of taking the drug. ONJ is more common in patients receiving bisphosphonate therapy for cancer with bony metastases as opposed to those receiving treatment for osteoporosis.<xref ref-type="bibr" rid="article-26552.r14">[14]</xref></p>
        <p>The IV bisphosphonates pamidronate and zoledronate are also associated with significant nephrotoxicity, which is rare among oral bisphosphonates. The risk of nephrotoxicity increases with larger doses, shorter infusion times, and more frequent dosing intervals.<xref ref-type="bibr" rid="article-26552.r15">[15]</xref>&#x000a0;The most common type of nephrotoxicity seen with pamidronate administration is collapsing focal segmental glomerulosclerosis. Renal toxicity due to pamidronate likely increases in patients with malignancy who also have other risk factors for renal impairment such as chronic kidney disease, hypercalcemia, multiple myeloma, hypertension, older age, treatment with chemotherapeutic drugs, and previous bisphosphonate treatment.</p>
        <p>There are reports of pamidronate causing other adverse effects like urticaria and atypical femoral fractures, but the number of such cases is small.<xref ref-type="bibr" rid="article-26552.r16">[16]</xref><xref ref-type="bibr" rid="article-26552.r17">[17]</xref></p>
      </sec>
      <sec id="article-26552.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Pamidronate is contraindicated for those with hypersensitivity to bisphosphonates or mannitol. It is also contraindicated in patients whose creatinine clearance is less than 30 mL/min and not found to have fatal calcium levels or severe bone disease secondary to multiple myeloma.<xref ref-type="bibr" rid="article-26552.r1">[1]</xref><xref ref-type="bibr" rid="article-26552.r10">[10]</xref></p>
      </sec>
      <sec id="article-26552.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients treated with pamidronate should have their kidney function closely monitored throughout their treatment with the medication. Clinicians should record serum creatinine before every infusion. In instances of renal deterioration, the patient should not receive the drug until creatinine rises to within 10% of the patient&#x02019;s baseline level. Electrolyte disturbances can also occur with the drug, and thus magnesium, potassium, phosphorus, calcium, and vitamin D levels should be monitored and corrected if necessary. Patients should also receive monitoring for albuminuria for 3&#x000a0;to 6 months after pamidronate infusion.<xref ref-type="bibr" rid="article-26552.r10">[10]</xref></p>
        <p>Close monitoring of a patient&#x02019;s creatinine clearance is vital as the administration protocol of pamidronate depends on this value. Infusion time is not affected with creatinine clearance values greater than 60 mL/min, but for values between 30 to 60 mL/min, it is recommended to either decrease the drug dose or infuse it over a longer period. Pamidronate infusion is not recommended in patients with creatinine clearance less than 30 mL/min except in cases of fatal calcium levels or those with severe bone disease due to multiple myeloma.<xref ref-type="bibr" rid="article-26552.r10">[10]</xref></p>
      </sec>
      <sec id="article-26552.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>A small number of cases describe symptomatic hypocalcemia following pamidronate administration. In each case, however, patients had pre-existing derangements contributing to their symptoms, including renal insufficiency and low vitamin D levels secondary to lifestyle, previous GI surgery, and medication history. Recommendations for the management of pamidronate overdose include appropriate correction of the electrolyte disturbance and pre-treatment supplementation with calcium and Vitamin D.<xref ref-type="bibr" rid="article-26552.r13">[13]</xref><xref ref-type="bibr" rid="article-26552.r18">[18]</xref></p>
      </sec>
      <sec id="article-26552.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pamidronate is frequently a therapeutic choice in managing Paget disease of bone, multiple myeloma, hypercalcemia of malignancy, and bone metastases of breast cancer.<xref ref-type="bibr" rid="article-26552.r2">[2]</xref><xref ref-type="bibr" rid="article-26552.r3">[3]</xref><xref ref-type="bibr" rid="article-26552.r4">[4]</xref><xref ref-type="bibr" rid="article-26552.r5">[5]</xref><xref ref-type="bibr" rid="article-26552.r6">[6]</xref>) Clinicians (including mid-level practitioners), nurses, pharmacists, and other interprofessional healthcare team members responsible for treating patients receiving this drug must be aware of the value and potential complications associated with this drug. Physicians should take charge of educating the patient about possible side effects of the medication, including osteonecrosis of the jaw, which requires discussion with the patient&#x02019;s dentist before any procedures.<xref ref-type="bibr" rid="article-26552.r14">[14]</xref>&#x000a0;</p>
        <p>Nephrotoxicity is another feared side effect of pamidronate, and careful monitoring of a patient&#x02019;s renal function by members of the healthcare team is paramount throughout treatment.<xref ref-type="bibr" rid="article-26552.r15">[15]</xref><xref ref-type="bibr" rid="article-26552.r10">[10]</xref>&#x000a0;Pharmacists should perform complete&#x000a0;medication reconciliation for the patient, recognize any potential drug-drug interactions, and report any concerns with the rest of the team. Nurses&#x000a0;should be knowledgeable about proper drug administration, be able to detect signs of possible adverse effects, and communicate regularly with the physician with any updates. [Level 1]</p>
        <p>The interprofessional team approach to pamidronate therapy can drive patient outcomes positively while limiting potential adverse events. [Level 5]</p>
      </sec>
      <sec id="article-26552.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26552&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26552">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26552/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26552">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26552.s11">
        <title>References</title>
        <ref id="article-26552.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ganesan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roane</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Bisphosphonate</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">29262103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Major</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lortholary</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abdi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Menssen</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Yunus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Body</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Quebe-Fehling</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seaman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.</article-title>
            <source>J Clin Oncol</source>
            <year>2001</year>
            <month>Jan</month>
            <day>15</day>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>558</fpage>
            <page-range>558-67</page-range>
            <pub-id pub-id-type="pmid">11208851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reagan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosner</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-7</page-range>
            <pub-id pub-id-type="pmid">24021907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kravets</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Paget's Disease of Bone: Diagnosis and Treatment.</article-title>
            <source>Am J Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>131</volume>
            <issue>11</issue>
            <fpage>1298</fpage>
            <page-range>1298-1303</page-range>
            <pub-id pub-id-type="pmid">29752905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Poznak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Somerfield</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Biermann</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Bosserman</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Clemons</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Dhesy-Thind</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Dillmon</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Eisen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Jagsi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Theriault</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Vandenberg</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Moy</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Dec</month>
            <day>10</day>
            <volume>35</volume>
            <issue>35</issue>
            <fpage>3978</fpage>
            <page-range>3978-3986</page-range>
            <pub-id pub-id-type="pmid">29035643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mhaskar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miladinovic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Djulbegovic</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonates in multiple myeloma: an updated network meta-analysis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Dec</month>
            <day>18</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD003188</fpage>
            <pub-id pub-id-type="pmid">29253322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zanatta</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Marcatto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ma&#x000f1;as</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Borba</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Use of pamidronate for osteoporosis treatment in public health care in Brazil.</article-title>
            <source>Rev Bras Reumatol Engl Ed</source>
            <year>2017</year>
            <season>Nov-Dec</season>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>514</fpage>
            <page-range>514-520</page-range>
            <pub-id pub-id-type="pmid">29173688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Daele</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Pamidronate in complex regional pain syndrome: effective therapy in CRPS.</article-title>
            <source>Neth J Med</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-4</page-range>
            <pub-id pub-id-type="pmid">26819355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drake</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Khosla</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonates: mechanism of action and role in clinical practice.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>83</volume>
            <issue>9</issue>
            <fpage>1032</fpage>
            <page-range>1032-45</page-range>
            <pub-id pub-id-type="pmid">18775204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Horvath</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Joshua</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Quach</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mollee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Talaulikar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Augustson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jaksic</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kalro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Zannettino</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.</article-title>
            <source>Intern Med J</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>47</volume>
            <issue>8</issue>
            <fpage>938</fpage>
            <page-range>938-951</page-range>
            <pub-id pub-id-type="pmid">28782211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Body</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonates for cancer patients: why, how, and when?</article-title>
            <source>Support Care Cancer</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>399</fpage>
            <page-range>399-407</page-range>
            <pub-id pub-id-type="pmid">12136223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siris</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Lyles</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Meunier</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Medical management of Paget's disease of bone: indications for treatment and review of current therapies.</article-title>
            <source>J Bone Miner Res</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>21 Suppl 2</volume>
            <fpage>P94</fpage>
            <page-range>P94-8</page-range>
            <pub-id pub-id-type="pmid">17229018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papapetrou</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate-associated adverse events.</article-title>
            <source>Hormones (Athens)</source>
            <year>2009</year>
            <season>Apr-Jun</season>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>96</fpage>
            <page-range>96-110</page-range>
            <pub-id pub-id-type="pmid">19570737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Bisphosphonate Related Jaw Osteonecrosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">30521192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate nephrotoxicity.</article-title>
            <source>Kidney Int</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>74</volume>
            <issue>11</issue>
            <fpage>1385</fpage>
            <page-range>1385-93</page-range>
            <pub-id pub-id-type="pmid">18685574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mubarik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chippa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <chapter-title>Postpartum Cardiomyopathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">30521191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bunta</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Odvina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Raisch</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>McKoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Omar</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Belknap</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hahr</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Samaras</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Langman</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.</article-title>
            <source>J Bone Joint Surg Am</source>
            <year>2013</year>
            <month>Feb</month>
            <day>20</day>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>297</fpage>
            <page-range>297-307</page-range>
            <pub-id pub-id-type="pmid">23426763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26552.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maalouf</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Odvina</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Sakhaee</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature.</article-title>
            <source>Endocr Pract</source>
            <year>2006</year>
            <season>Jan-Feb</season>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-53</page-range>
            <pub-id pub-id-type="pmid">16524863</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
